ADMAADMA Biologics, Inc.
Is it safe?
One accounting flag to check: a safe balance sheet and comfortable debt (AA), but an accounting pattern worth a look (common in fast growers) and big price swings.
Financially healthy, low distress risk Altman Z-score, a bankruptcy-risk model from five balance-sheet ratios.
Several accounting flags in the manipulation-likely range Beneish M-score, a forensic model that detects earnings-manipulation patterns (receivables outrunning sales, margins slipping, accrual-heavy profit).
Mixed fundamental signals Piotroski F-score, nine pass/fail tests of year-over-year financial health across profitability, balance sheet and efficiency. 7 to 9 is strong, 0 to 3 weak.
Rock-solid balance sheet, low leverage. A rule of thumb on leverage, not a credit rating.
Large price swings, high volatility. Worst drawdown -86% · now 49% below its 52-week high.
Unless marked, from SEC EDGAR, as of Dec 31, 2025.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. Altman sits structurally low for utilities and pipelines; Beneish runs high for fast growers, since sales growth alone lifts it; banks and REITs are excluded.
Can ADMA take a bad year?
ADMA Biologics, Inc. carries $61M of net debt at 0.26× EBITDA: a load its earnings can carry.
Net debt · as at Q2 2026 · under two and a half years of EBITDA, comfortable
- Net debt / EBITDA
- 0.26×
Net debt / EBITDA
- Altman Z-score
- 10.48
Altman Z-score · safe zone, above 3
- Interest cover
- 25.4×
Interest cover · operating profit covers the interest bill several times over
Details›
- Total debtQ2 2026
- $197M
- Cash and short-term investments
- $136M
- Net debt
- $61M
- EBITDA, trailing twelve months
- $232M
- Operating profit, trailing twelve months
- $224M
- Debt / equity
- 0.48×
- Total debt / EBITDA
- 0.85×
- Annualised volatilitytwo years of daily moves
- 56%
- Worst drawdown on file
- −86%
- Below its 52-week high
- 49%
Balance sheet from SEC filings; drawdown and volatility from end-of-day closes; Altman Z from the filed statements.